Kynexis

Cognitive impairment associated with schizophrenia (CIAS) is a major cause of disability for over 24 million people affected with schizophrenia worldwide. We're taking a biomarker-based approach to understand the causal human biology in CIAS to advance KYN-5356, a potential first-in-class small molecule KAT-II inhibitor in development for CIAS. Learn more about our approach: https://bit.ly/3OQohbf

Our team of trailblazers pioneering the next era of treatments for brain diseases came together for an incredible team-building event filled with food, fun, and camaraderie. At Kynexis, we’re committed to our mission of enabling a better life for people suffering from schizophrenia, and these moments of connection strengthen our drive to make a difference. #biotechnology #innovation

Meet our #ScientificAdvisoryBoard. With deep experience in schizophrenia and cognition, we’re excited to have Philip D. Harvey as we work to enable a better life for people with schizophrenia. Read about our inaugural members: https://lnkd.in/eKckHxWS #innovation #drugdevelopment #biotechnology

Did you hear about the formation of our #ScientificAdvisoryBoard? We're pleased to welcome all our members, including Thomas Laughren, who shares his perspective on the treatment landscape for schizophrenia and the potential of KYN-5356. Learn about our board members: https://bit.ly/3Vu8C5b #biotechnology #innovation

Yesterday, we announced the formation of our #ScientificAdvisoryBoard (SAB). SAB Chair and Scientific Co-founder Carol Tamminga will use her expertise and insights into the mechanisms underlying schizophrenia to help us advance our first-in-class KAT-II inhibitor, KYN-5356, as a potential treatment for cognitive impairment associated with schizophrenia (CIAS). Read more here: https://bit.ly/3Vu8C5b #biotechnology #innovation #drugdevelopment

We are thrilled to announce the appointment of our #ScientificAdvisoryBoard! Our diverse group of scientific experts will work with our leadership team to advance KYN-5356, a first-in-class small molecule KAT-II inhibitor, in development for the treatment of cognitive impairment associated with schizophrenia (CIAS). Learn more about our members: https://bit.ly/3Vu8C5b #innovation #drugdevelopment #biotechnology

Our human biology-based approach combines human genetics, biomarkers, and deep phenotyping to advance KYN-5365. This uniquely positions our program for success in cognitive impairment associated with #schizophrenia (CIAS) and potentially other indications as well Learn about our approach: https://bit.ly/3OQohbf #innovation #biotechnology #precisionmedicine #drugdevelopment

Today, we celebrate and recognize our incredible team at Kynexis. Thank you for embodying our values of conviction, collaboration, and kindness, and for your dedication to enabling a better life for people suffering from schizophrenia. #EmployeeAppreciationDay #biotechnology

Did you know that cognitive impairment associated with schizophrenia (CIAS) is a major cause of disability for over 24 million affected people worldwide? At Kynexis, we're pioneering the first precision medicine as a potential treatment of CIAS to enable a better life for people suffering with #schizophrenia. Learn more about our approach: https://bit.ly/3OQohbf #biotechnology #innovation #drugdevelopment

At Kynexis, our team of trailblazers is pioneering the next era of treatments for brain diseases by advancing the first precision medicine for cognitive impairment associated with schizophrenia (CIAS). The important work we're doing is guided by three principles - conviction, connection, and kindness. Learn more about us and our work: https://bit.ly/3HEywLu #biotechnology #innovation